Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report)'s stock price was up 7.5% on Wednesday. The company traded as high as $22.40 and last traded at $22.2070. 357,603 shares were traded during trading, a decline of 82% from the average session volume of 2,040,564 shares. The stock had previously closed at $20.65.
Analysts Set New Price Targets
A number of brokerages have issued reports on BEAM. Canaccord Genuity Group cut their target price on shares of Beam Therapeutics from $79.00 to $78.00 and set a "buy" rating on the stock in a report on Wednesday, November 4th. William Blair upgraded Beam Therapeutics to a "strong-buy" rating in a research report on Wednesday, September 23rd. HC Wainwright reissued a "buy" rating on shares of Beam Therapeutics in a report on Tuesday, October 27th. Guggenheim reduced their price objective on Beam Therapeutics from $55.00 to $51.00 and set a "buy" rating for the company in a research report on Thursday, November 5th. Finally, Wedbush upped their price objective on Beam Therapeutics from $30.00 to $33.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $47.64.
View Our Latest Research Report on BEAM
Beam Therapeutics Trading Up 5.8%
The business's 50 day moving average is $24.85 and its two-hundred day moving average is $27.77. The company has a quick ratio of 13.00, a current ratio of 13.01 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $2.26 billion, a P/E ratio of -21.00 and a beta of 2.23.
Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last announced its earnings results on Tuesday, November 3rd. The company reported ($1.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.11). Beam Therapeutics had a negative net margin of 73.04% and a negative return on equity of 32.76%. The company had revenue of $0.31 million during the quarter, compared to the consensus estimate of $8.75 million. During the same quarter in the prior year, the company earned ($1.10) EPS. The business's quarterly revenue was down 96.8% on a year-over-year basis. Analysts expect that Beam Therapeutics Inc. will post -4.65 EPS for the current year.
Insider Transactions at Beam Therapeutics
In other Beam Therapeutics news, CEO John Evans sold 25,000 shares of Beam Therapeutics stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $23.57, for a total value of $589,250.00. Following the transaction, the chief executive officer owned 1,047,205 shares in the company, valued at approximately $24,682,621.85. The trade was a 2.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 3.80% of the company's stock.
Hedge Funds Weigh In On Beam Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Versant Capital Management Inc grew its holdings in shares of Beam Therapeutics by 123.6% during the 3rd quarter. Versant Capital Management Inc now owns 1,239 shares of the company's stock valued at $30,000 after acquiring an additional 685 shares in the last quarter. Global Retirement Partners LLC increased its stake in shares of Beam Therapeutics by 297.3% in the third quarter. Global Retirement Partners LLC now owns 1,490 shares of the company's stock worth $36,000 after acquiring an additional 1,115 shares during the last quarter. Hollencrest Capital Management purchased a new stake in shares of Beam Therapeutics during the first quarter worth $43,000. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Beam Therapeutics during the second quarter worth $43,000. Finally, Fulcrum Asset Management LLP acquired a new stake in Beam Therapeutics during the third quarter valued at $51,000. Institutional investors and hedge funds own 99.68% of the company's stock.
Beam Therapeutics Company Profile
(
Get Free Report)
Beam Therapeutics is a biotechnology company developing genetic medicines using base editing, a form of gene editing designed to make precise changes to DNA. Its platform includes base-editing technologies and delivery systems intended to address diseases by altering the genetic instructions involved in their development. The company's research and development programs include potential treatments for genetic diseases, including sickle cell disease. Its work spans medicines made by editing a patient's cells outside the body as well as approaches intended to deliver gene editing directly to cells in the body.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Beam Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beam Therapeutics wasn't on the list.
While Beam Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.